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Abstract
Objective. Calcinosis is a major cause of morbidity in JDM and has previously been linked to anti-NXP2
autoantibodies, younger age at disease onset and more persistent disease activity. This study aimed to
investigate the clinical associations of anti-NXP2 autoantibodies in patients with JDM stratified by age at
disease onset.
Methods. A total of 285 patients with samples and clinical data were recruited via the UK Juvenile
Dermatomyositis Cohort and Biomarker Study. The presence of anti-NXP2 was determined by both
immunoprecipitation and ELISA. Logistic regression analysis was performed to assess the age-dependent
relationship between anti-NXP2 and the development of calcinosis and disease activity measures.
Results. We identified anti-NXP2 autoantibodies in 56 patients (20%). While in all patients younger age at
disease onset was associated with an increased risk of calcinosis and this relationship was nearly linear,
anti-NXP2 autoantibodies substantially increased the risk of calcinosis across all ages (P= 0.025) and were
detectable prior to calcinosis development. Children with anti-NXP2 autoantibodies had a greater degree
of weakness (median lowest ever Childhood Myositis Assessment Score 29.6 vs 42) and were less likely to
be in remission at 2 years post-diagnosis. No difference in disease activity was seen 4 years post-
diagnosis.
Conclusion. Children diagnosed at a young age have a high risk of calcinosis regardless of autoantibody
status. However, the presence of anti-NXP2 autoantibodies substantially increases the risk of calcinosis
across all ages and is associated with disease severity.
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Introduction
Our group has previously demonstrated that antibodies to
a 140 kDa protein detected by protein immunoprecipitation
(known as anti-p140 or P140) in JDM were strongly asso-
ciated with the development of calcinosis, a major cause of
morbidity [1]. The presence of autoantibodies to a 142 kDa
antigen (anti-MJ) in JDM has also been shown by others to
be associated with a severe disease course, worse func-
tional status and persistent disease activity [2]. It is now
clear that the target of these autoantibodies is a 140 kDa
protein, NXP2 (molecular weight 140 kDa). Anti-NXP2 auto-
antibodies are common in JDM and identifiable in 1323%
of patients [1, 2].
JDM is a heterogeneous disease and autoantibodies
are potentially useful biomarkers to divide patients into
homogeneous subgroups and inform on prognosis. Anti-
NXP2 autoantibodies are of particular interest, given their
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frequency in JDM and their association with important
disease features such as calcinosis, a major cause of
morbidity. In addition to autoantibody status, age at dis-
ease onset has also been shown to influence the clinical
phenotype and overall prognosis in JDM, although the
nature of the relationship between age at disease onset
and outcome has been variably reported [3, 4].
Here we analyse the clinical associations of anti-NXP2
measured by ELISA and protein immunoprecipitation
within an extended and large cohort of juvenile myositis
patients stratified by age of onset. We specifically assess
the relationships between autoantibody status, calcinosis
and disease activity.
Methods
Patients
Patient serum samples and clinical data were obtained
through the UK Juvenile Dermatomyositis Cohort and
Biomarker Study (JDCBS). The JDCBS is a large cohort
of UK patients with idiopathic inflammatory myopathies
(IIMs), the majority with JDM [5]. Patients are recruited
consecutively on presentation to paediatric rheumatology
departments across the UK. Children and young people
416 years of age are included based on a diagnosis of
definite or probable JDM or PM by Bohan and Peter cri-
teria [6], as well as JDM or PM with overlap CTD features.
Multicentre research ethics approval was obtained for the
JDCBS and parental consent for children and consent or
age-appropriate assent was obtained for all patients in
accordance with the Declaration of Helsinki. The JDCBS
Steering Committee approved this project and biological
samples and clinical data were provided in accordance
with JDCBS ethics and consent.
Remission in JDM was defined as a full-strength
Childhood Myositis Assessment Score (CMAS) >48 [7],
the absence of skin disease (no rash, no Gottron’s, no
oedema and no ulceration) and a Physician’s Global
Assessment Score (PGAS) <1. While this definition of re-
mission has not been validated, all are standard outcome
measures in JDM. Where possible, we also utilized the
recently proposed PRINTO criteria for disease inactivity
in JDM, defined as at least three of the following criteria:
creatinine kinase 4150, CMAS 548, manual muscle test
(MMT) 578 and PGAS 40.2 [8].
Autoantibody detection
Immunoprecipitation of radio-labelled K562 cells was per-
formed on all samples to determine the presence of auto-
antibodies. Anti-NXP2 ELISA was subsequently
performed on all samples. Patients were classified as
anti-NXP2 positive if a 140 kDa band was seen on immu-
noprecipitation and anti-NXP2 ELISA was subsequently
positive.
Immunoprecipitation
Ten microlitres of sera were mixed with 2 mg of protein
ASepharose beads (Sigma, St Louis, MO, USA) in immu-
noprecipitation (IPP) buffer (10 mM TrisHCl, pH 8.0,
500 mM NaCl, 0.1% v/v Igepal) at room temperature for
30 min. Beads were washed in IPP buffer prior to the add-
ition of 120ml of [35S]methionine-labelled K562 cell extract
in IPP buffer. Samples were mixed at 4C for 2 h. Beads
were washed in IPP buffer and Tris-buffered saline (TBS)
(10 mM TrisHCl, pH 7.4, 150 mM NaCl) before being re-
suspended in 50ml of SDS sample buffer (Sigma). After
heating, proteins were fractionated by 9% SDS-PAGE
gels, enhanced, fixed and dried. Labelled proteins were
analysed by autoradiography.
ELISA
ELISA was conducted as previously described [9], with
some modifications. Ninety-six-well polystyrene plates
were coated with rNXP2 (Origene Technologies,
Rockville, MD, USA) at 4C for 16 h. Samples were diluted
to 1:200. Secondary antibodies were conjugated goat
anti-human IgG/M (Sigma). Tetramethylbenzidine liquid
substrate (Sigma) was then added. All samples were
tested in duplicate and optical density was read using
an automatic plate reader. The negative cut-off was
defined as >3 S.D. above the mean of 42 normal healthy
(adult) serum controls.
Data analysis
Multivariate regression analyses were performed using
generalized additive models within R [10], which allows
for the possibility of non-linear relationships between cov-
ariates and response variables [11]. Within this framework,
models were used to assess the significance of age at
disease onset and anti-NXP2 in relation to calcinosis as
well as disease outcome 2 and >4 years post-diagnosis.
Disease duration was adjusted for. Potential differences
between two groups were assessed using chi-squared
analysis with Yates’s continuity correction. The
MannWhitney U test was used to compare non-normally
distributed continuous data.
Results
Demographic data and key findings are summarized in
Table 1.
Autoantibody detection
Of the 365 patients enrolled in the JDCBS at the time of
analysis, 285 (78%) had both data and serum available.
This group was representative of the cohort as a whole,
showing no significant differences in gender (72% vs 68%
female), age at disease onset (median 6.2 vs 6.7 years) or
JDM clinical type (12% vs 14% JDM overlap) compared
with those patients not analysed.
Anti-NXP2 autoantibodies were identified in 56/285
(20%) patients. Two further patients were positive by
anti-NXP2 ELISA but did not have a 140 kDa band on
immunoprecipitation. Further analysis was carried out on
only those patients definitively positive using both
techniques.
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Calcinosis
Overall, 33% of patients developed calcinosis during the
follow-up period. Age at disease onset influenced the like-
lihood of calcinosis allowing for the duration of disease
and there was a significant decrease in calcinosis with
increasing age at disease onset [odds ratio (OR) 0.90,
95% CI 0.83, 0.97, P= 0.005]. Furthermore, this relation-
ship with age proved to be near linear, a striking result
given the flexibility of the model meant there were no
prior constraints on its shape (Fig. 1).
There was a significant association with anti-NXP2
autoantibodies and calcinosis: 43% anti-NXP2-positive
patients developed calcinosis vs 30% anti-NXP2-negative
patients (OR 2.10, 95% CI 1.10, 4.01, P= 0.025 un-
adjusted for age, P= 0.039 adjusted). The presence of
anti-NXP2 autoantibodies increased the risk of calcinosis
after allowance for the possible effects of other variables,
including age.
As some patients were recruited an appreciable time
after their initial diagnosis, information on when calcinosis
was first noted was not always available. However, seven
children with anti-NXP2 autoantibodies developed calci-
nosis after their first study visit and all of these had anti-
NXP2 autoantibodies present in blood samples predating
calcinosis development (taken 2 months4 years after dis-
ease onset). The average time to develop calcinosis in this
group was 5.3 years (range 1.213 years). Thirty-two
children without anti-NXP2 autoantibodies developed cal-
cinosis after their first study visit and the average time to
calcinosis was similar at 4.1 years after disease onset
(range 010.9 years).
Muscle weakness
Children with anti-NXP2 autoantibodies had a lower median
lowest ever CMAS, corresponding to a greater degree of
muscle weakness, compared with those without anti-
NXP2 autoantibodies {29.6 [interquartile range (IQR) 1843]
vs 42 (IQR 3148)} and this was statistically significant
(P< 0.001). Furthermore, 53% of children with anti-NXP2
had a lowest ever CMAS430, corresponding to a moderate
or severe degree of weakness [7], compared with just 25%
of those children without anti-NXP2 (P< 0.001).
Disease outcome in JDM
Disease outcome was assessed 2 years post-diagnosis
and at the last clinic visit, providing this was at least 4
years post-diagnosis (mean 7.9 years). Data at 2 years
post-diagnosis were not yet available in children who had
been diagnosed with JDM <2 years previously, had been
recruited into the study>2 years post-diagnosis or had not
been reviewed 2028 months post-diagnosis. Information
was available for 152 children 2 years post-diagnosis (25
with anti-NXP2 autoantibodies) and 136 children >4 years
post-diagnosis (24 with anti-NXP2 autoantibodies).
Using our own predefined definition of remission, chil-
dren with anti-NXP2 antibodies were less likely to be in
remission 2 years post-diagnosis compared with those
without anti- NXP2 (8% vs 32%; OR 0.23, 95% CI 0.05,
1.05, P= 0.04). Using the recently proposed PRINTO defin-
ition of disease inactivity in JDM [8], fewer children with
anti-NXP2 had inactive disease 2 years post-diagnosis
(37.5% vs 48%), but this did not reach significance.
Outcomes >4 years post-diagnosis were similar in the
TABLE 1 Demographic data and key findings of 285 patients analysed
All patients Anti-NXP2 positive
Female, n/N (%) 206/285 (72) 41/56 (73)
IIM subtypea, n/N (%)
DM 242/285 (85) 55/56 (98)
PM 1/278 (0.4) 0
Overlap 33/285 (12) 1/56 (2)b
Age at onset, average (IQR), years 6.2 (410) 6.5 (410)
Time to diagnosis, average (IQR), months 4 (210) 4 (210)
Length of follow-up, average (IQR), years 9 (512) 9 (512)
Proportion with calcinosis, n/N (%) 94/283 (29) 24/56 (43), P= 0.025
Lowest ever CMAS score, average (IQR) 40 (2748) 29.6 (1843), P< 0.001
IQR: interquartile range; IIM: idiopathic inflammatory myopathy; CMAS: Childhood Myositis Assessment Score. aIn addition to the
diagnostic categories listed, nine juvenile patients were labelled as other IIM or focal myositis. bThis patient had JDMscleroderma
overlap. Bold text indicates significant P-values. Demographic data were similar between anti-NXP2-positive and -negative
groups.
FIG. 1 The effect of anti-NXP2 autoantibodies on the risk
of calcinosis by age at disease onset (with 95% CI)
A near-linear relationship is seen between younger age at
disease onset and increased risk of calcinosis.
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two groups, irrespective of the definition used (our own
criteria, 47% vs 50%; PRINTO criteria, 72% vs 73%).
Discussion
This study shows that anti-NXP2 autoantibodies are the
most common autoantibody identifiable in our JDM cohort
and can be identified in one in five UK children with JDM.
They are a potentially important clinical biomarker and can
both facilitate diagnosis and provide important prognostic
information, particularly with regard to calcinosis
development.
Younger children with JDM are believed by some spe-
cialist clinicians to have more aggressive disease, but
recent studies have challenged this view [4]. We have
clearly demonstrated that children presenting at a
younger age have a higher risk of developing calcinosis,
a major cause of morbidity. The presence of anti-NXP2
autoantibodies substantially increases the risk of calcino-
sis across all ages.
Anti-NXP2 autoantibodies were associated with a
greater degree of muscle weakness as determined by
CMAS, suggesting more severe disease. This difference
is of clinical significance and children with anti-NXP2
autoantibodies were more likely to have a moderate or
severe degree of clinical weakness [7].
In JDM, the development of calcinosis has previously
been associated with a delayed diagnosis, a chronic
disease course and inadequately treated disease [12].
In our cohort, no difference in time from symptom onset
to diagnosis was identified between the anti-NXP2-posi-
tive and anti-NXP2-negative groups. We investigated the
prevalence of disease remission in JDM at two time points
using two different definitions of disease inactivity. While a
significant association between anti-NXP2 autoantibody
status and more persistent disease activity 2 years
post-diagnosis was suggested using our own definition
of remission, the CIs were wide. We were unable to clearly
demonstrate a significant relationship using the recently
proposed PRINTO criteria, although the same trend
existed. Persistent disease activity remains a possible
mechanism driving calcinosis development in children
with anti-NXP2 autoantibodies, but larger patient numbers
and validated remission criteria are required to firmly
establish the nature of any association.
In summary, anti-NXP2 autoantibodies are associated
with features of severe disease in JDM. The development
of calcinosis in JDM is influenced by both age at disease
onset and anti-NXP2 autoantibody status and both factors
must be considered when attempting to predict the risk of
this clinically important complication.
Rheumatology key messages
. Earlier age at disease onset is associated with
greater risk of calcinosis in JDM.
. Anti-NXP2 substantially increases the risk of calci-
nosis across all age groups in JDM.
. Anti-NXP2 autoantibodies are associated with fea-
tures of severe disease in JDM.
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Ultrasonographic diagnosis of posterior
interosseous nerve entrapment due to ganglion
cyst in a patient with rheumatoid arthritis
A 74-year-old man with RA was seen due to weakness
in the fingers of his right hand. He was receiving LEF
(20 mg/day) and prednisolone (10 mg/day) treatment.
Physical examination showed weakness (1/5) of the
finger extensors (drop finger). Laboratory tests yielded
increased CRP (6.4 mg/l, normal range 03), ESR
(56 mm/h, normal range 020) and RF (192 IU/ml, normal
range 014) levels. Electrodiagnostic evaluations were
consistent with severe and partial neuropathy of the
right posterior interosseous nerve (PIN). US imaging
clearly demonstrated a ganglion cyst compressing the
PIN (Fig. 1). As the ganglion could not be drained,
US-guided intervention was finalized with intralesional
betamethasone injection. The patient refused surgery, as
his pain (but not weakness) subsided.
A ganglion or synovial cyst is a benign tumour-like mass
that usually occurs near the joints or tendon sheaths, most
commonly in the wrist and hand [1]. Although they are
usually asymptomatic, they can manifest with various
complaints, especially if they cause any sort of nerve
entrapment [2]. Herein we show that US is a convenient
imaging tool for illustrating not only the clinical conditions
related to RA (rheumatoid nodules, synovial cysts,
etc.) but also secondary/pertinent complications of such
manifestations, i.e. peripheral nerve compression.
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FIG. 1 US imaging (axial view) shows an anechoic (gan-
glion), lobulated cyst (asterisk) compressing the posterior
interosseous nerve (white arrow) distal to its branching
from the radial nerve at the level of the radial head (R)
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